MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: BioPharmaceuticals _ Orphan & Rare Diseases
Astria Therapeutics, Inc. (NASDAQ: ATXS)*, formerly, Catabasis Pharmaceuticals (NASDAQ:CATB)
Finance & Acquisitions: Catabasis
Parents
Astria Therapeutics, Inc. (NASDAQ: ATXS)*, formerly, Catabasis Pharmaceuticals (NASDAQ:CATB)
Children
2010: Catabasis Pharmaceuticals, Inc. Secures $14.5 Million Second Tranche in Series A Financing (2010)
2013: Amt: $9.75M, Series B (2013)
2021: Catabasis Pharmaceuticals no more: Meet Astria Therapeutics, hoping to be a phoenix from the flames
Catabasis Pharma Inc (CATB)_nasdaq
Catabasis Pharma Inc (CATB)_research.investors.com
In Apri 2010l, Catabasis announced it had completed a $39.6 million Series A financing led by SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures.
Proceeds from the second tranche will be used to progress the company’s lead compound to treat type 2 diabetes into clinical studies
Jumps
*Key People: Catabasis
Organization & Developments: Catabasis